A BRISC-SHMT Complex Deubiquitinates IFNAR1 and Regulates Interferon Responses

Cell Reports

Volumn 5, Issue 1, 2013, Pages 180-193

  Zheng, Hui ^a   Gupta, Vibhor ^b   Patterson Fortin, Jeffrey ^b   Bhattacharya, Sabyasachi ^a   Katlinski, Kanstantsin ^a   Wu, Junmin ^b   Varghese, Bentley ^a   Carbone, Christopher J ^a   Aressy, Bernadette ^b   Fuchs, Serge Y ^a   Greenberg, Roger A ^b  

^a UNIVERSITY OF PENNSYLVANIA SCHOOL OF VETERINARY MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; GLYCINE HYDROXYMETHYLTRANSFERASE; INTERLEUKIN 1BETA CONVERTING ENZYME; MEMBRANE PROTEIN; TYPE 1 INTERFERON RECEPTOR CHAIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; ATTENUATION; CELL FUNCTION; CELL METABOLISM; CONTROLLED STUDY; ENDOCYTOSIS; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME REGULATION; FEMALE; IMMUNOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; LYSOSOME; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; UBIQUITINATION;

MUS;

ANIMALS; FEMALE; GLYCINE HYDROXYMETHYLTRANSFERASE; HEK293 CELLS; HELA CELLS; HUMANS; INTERFERONS; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; MULTIPROTEIN COMPLEXES; RECEPTOR, INTERFERON ALPHA-BETA; RNA, SMALL INTERFERING; UBIQUITINATION; UBIQUITINS;

EID: 84885852890     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2013.08.025     Document Type: Article

References (47)

1. Agrawal H., Jacob N., Carreras E., Bajana S., Putterman C., Turner S., Neas B., Mathian A., Koss M.N., Stohl W., et al. Deficiency of type I IFN receptor in lupus-prone New Zealand mixed 2328 mice decreases dendritic cell numbers and activation and protects from disease. J.Immunol. 2009, 183:6021-6029.
2. Amerik A.Y., Hochstrasser M. Mechanism and function of deubiquitinating enzymes. Biochim. Biophys. Acta 2004, 1695:189-207.
3. Andrei C., Dazzi C., Lotti L., Torrisi M.R., Chimini G., Rubartelli A. The secretory route of the leaderless protein interleukin 1beta involves exocytosis of endolysosome-related vesicles. Mol. Biol. Cell 1999, 10:1463-1475.
4. Ciechanover A., Schwartz A.L. The ubiquitin system: pathogenesis of human diseases and drug targeting. Biochim. Biophys. Acta 2004, 1695:3-17.
5. Clague M.J., Urbé S. Endocytosis: the DUB version. Trends Cell Biol. 2006, 16:551-559.
6. Cohn M.A., Kowal P., Yang K., Haas W., Huang T.T., Gygi S.P., D'Andrea A.D. A UAF1-containing multisubunit protein complex regulates the Fanconi anemia pathway. Mol. Cell 2007, 28:786-797.
7. Cooper E.M., Cutcliffe C., Kristiansen T.Z., Pandey A., Pickart C.M., Cohen R.E. K63-specific deubiquitination by two JAMM/MPN+ complexes: BRISC-associated Brcc36 and proteasomal Poh1. EMBO J. 2009, 28:621-631.
8. Cooper E.M., Boeke J.D., Cohen R.E. Specificity of the BRISC deubiquitinating enzyme is not due to selective binding to Lys63-linked polyubiquitin. J.Biol. Chem. 2010, 285:10344-10352.
9. Feng L., Wang J., Chen J. The Lys63-specific deubiquitinating enzyme BRCC36 is regulated by two scaffold proteins localizing in different subcellular compartments. J.Biol. Chem. 2010, 285:30982-30988.
10. Fuchs S.Y. Ubiquitination-mediated regulation of interferon responses. Growth Factors 2012, 30:141-148.
11. Fuchs S.Y. Hope and fear for interferon: the receptor-centric outlook on the future of interferon therapy. J.Interferon Cytokine Res. 2013, 33:211-225.
12. Gabay C., Lamacchia C., Palmer G. IL-1 pathways in inflammation and human diseases. Nat Rev Rheumatol 2010, 6:232-241.
13. Goldman L.A., Zafari M., Cutrone E.C., Dang A., Brickelmeier M., Runkel L., Benjamin C.D., Ling L.E., Langer J.A. Characterization of antihuman IFNAR-1 monoclonal antibodies: epitope localization and functional analysis. J.Interferon Cytokine Res. 1999, 19:15-26.
14. Gough D.J., Messina N.L., Clarke C.J., Johnstone R.W., Levy D.E. Constitutive type I interferon modulates homeostatic balance through tonic signaling. Immunity 2012, 36:166-174.
15. Haglund K., Dikic I. The role of ubiquitylation in receptor endocytosis and endosomal sorting. J.Cell Sci. 2012, 125:265-275.
16. Huang T.T., Nijman S.M., Mirchandani K.D., Galardy P.J., Cohn M.A., Haas W., Gygi S.P., Ploegh H.L., Bernards R., D'Andrea A.D. Regulation of monoubiquitinated PCNA by DUB autocleavage. Nat. Cell Biol. 2006, 8:339-347.
17. Huangfu W.C., Fuchs S.Y. Ubiquitination-dependent regulation of signaling receptors in cancer. Genes Cancer 2010, 1:725-734.
18. Karaghiosoff M., Steinborn R., Kovarik P., Kriegshäuser G., Baccarini M., Donabauer B., Reichart U., Kolbe T., Bogdan C., Leanderson T., et al. Central role for type I interferons and Tyk2 in lipopolysaccharide-induced endotoxin shock. Nat. Immunol. 2003, 4:471-477.
19. Kimura Y., Tanaka K. Regulatory mechanisms involved in the control of ubiquitin homeostasis. J.Biochem. 2010, 147:793-798.
20. Kumar K.G., Tang W., Ravindranath A.K., Clark W.A., Croze E., Fuchs S.Y. SCF(HOS) ubiquitin ligase mediates the ligand-induced down-regulation of the interferon-alpha receptor. EMBO J. 2003, 22:5480-5490.
21. Kumar K.G., Krolewski J.J., Fuchs S.Y. Phosphorylation and specific ubiquitin acceptor sites are required for ubiquitination and degradation of the IFNAR1 subunit of type I interferon receptor. J.Biol. Chem. 2004, 279:46614-46620.
22. Kumar K.G., Barriere H., Carbone C.J., Liu J., Swaminathan G., Xu P., Li Y., Baker D.P., Peng J., Lukacs G.L., Fuchs S.Y. Site-specific ubiquitination exposes a linear motif to promote interferon-alpha receptor endocytosis. J.Cell Biol. 2007, 179:935-950.
23. Kumar K.G., Varghese B., Banerjee A., Baker D.P., Constantinescu S.N., Pellegrini S., Fuchs S.Y. Basal ubiquitin-independent internalization of interferon alpha receptor is prevented by Tyk2-mediated masking of a linear endocytic motif. J.Biol. Chem. 2008, 283:18566-18572.
24. Liu J., Plotnikov A., Banerjee A., Suresh Kumar K.G., Ragimbeau J., Marijanovic Z., Baker D.P., Pellegrini S., Fuchs S.Y. Ligand-independent pathway that controls stability of interferon alpha receptor. Biochem. Biophys. Res. Commun. 2008, 367:388-393.
25. Liu J., HuangFu W.C., Kumar K.G., Qian J., Casey J.P., Hamanaka R.B., Grigoriadou C., Aldabe R., Diehl J.A., Fuchs S.Y. Virus-induced unfolded protein response attenuates antiviral defenses via phosphorylation-dependent degradation of the type I interferon receptor. Cell Host Microbe 2009, 5:72-83.
26. McBride J.M., Jiang J., Abbas A.R., Morimoto A., Li J., Maciuca R., Townsend M., Wallace D.J., Kennedy W.P., Drappa J. Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo-controlled, double-blind, dose-escalation study. Arthritis Rheum. 2012, 64:3666-3676.
27. Nacionales D.C., Kelly-Scumpia K.M., Lee P.Y., Weinstein J.S., Lyons R., Sobel E., Satoh M., Reeves W.H. Deficiency of the type I interferon receptor protects mice from experimental lupus. Arthritis Rheum. 2007, 56:3770-3783.
28. Nijman S.M., Huang T.T., Dirac A.M., Brummelkamp T.R., Kerkhoven R.M., D'Andrea A.D., Bernards R. The deubiquitinating enzyme USP1 regulates the Fanconi anemia pathway. Mol. Cell 2005, 17:331-339.
29. Patterson-Fortin J., Shao G., Bretscher H., Messick T.E., Greenberg R.A. Differential regulation of JAMM domain deubiquitinating enzyme activity within the RAP80 complex. J.Biol. Chem. 2010, 285:30971-30981.
30. Piehler J., Thomas C., Garcia K.C., Schreiber G. Structural and dynamic determinants of type I interferon receptor assembly and their functional interpretation. Immunol. Rev. 2012, 250:317-334.
31. Py B.F., Kim M.S., Vakifahmetoglu-Norberg H., Yuan J. Deubiquitination of NLRP3 by BRCC3 critically regulates inflammasome activity. Mol. Cell 2013, 49:331-338.
32. Qian J., Zheng H., Huangfu W.C., Liu J., Carbone C.J., Leu N.A., Baker D.P., Fuchs S.Y. Pathogen recognition receptor signaling accelerates phosphorylation-dependent degradation of IFNAR1. PLoS Pathog. 2011, 7:e1002065.
33. Reyes-Turcu F.E., Wilkinson K.D. Polyubiquitin binding and disassembly by deubiquitinating enzymes. Chem. Rev. 2009, 109:1495-1508.
34. Scheer J.B., Mackey A.D., Gregory J.F. Activities of hepatic cytosolic and mitochondrial forms of serine hydroxymethyltransferase and hepatic glycine concentration are affected by vitamin B-6 intake in rats. J.Nutr. 2005, 135:233-238.
35. Schroder K., Tschopp J. The inflammasomes. Cell 2010, 140:821-832.
36. Shao G., Lilli D.R., Patterson-Fortin J., Coleman K.A., Morrissey D.E., Greenberg R.A. The Rap80-BRCC36 de-ubiquitinating enzyme complex antagonizes RNF8-Ubc13-dependent ubiquitination events at DNA double strand breaks. Proc. Natl. Acad. Sci. USA 2009, 106:3166-3171.
37. Shao G., Patterson-Fortin J., Messick T.E., Feng D., Shanbhag N., Wang Y., Greenberg R.A. MERIT40 controls BRCA1-Rap80 complex integrity and recruitment to DNA double-strand breaks. Genes Dev. 2009, 23:740-754.
38. Sobhian B., Shao G., Lilli D.R., Culhane A.C., Moreau L.A., Xia B., Livingston D.M., Greenberg R.A. RAP80 targets BRCA1 to specific ubiquitin structures at DNA damage sites. Science 2007, 316:1198-1202.
39. Sowa M.E., Bennett E.J., Gygi S.P., Harper J.W. Defining the human deubiquitinating enzyme interaction landscape. Cell 2009, 138:389-403.
40. Stewart T.A. Neutralizing interferon alpha as a therapeutic approach to autoimmune diseases. Cytokine Growth Factor Rev. 2003, 14:139-154.
41. Taniguchi T., Takaoka A. A weak signal for strong responses: interferon-alpha/beta revisited. Nat. Rev. Mol. Cell Biol. 2001, 2:378-386.
42. Trinchieri G. Type I interferon: friend or foe?. J.Exp. Med. 2010, 207:2053-2063.
43. Ventii K.H., Wilkinson K.D. Protein partners of deubiquitinating enzymes. Biochem. J. 2008, 414:161-175.
44. Verma R., Aravind L., Oania R., McDonald W.H., Yates J.R., Koonin E.V., Deshaies R.J. Role of Rpn11 metalloprotease in deubiquitination and degradation by the 26S proteasome. Science 2002, 298:611-615.
45. Watkins L.R., Hansen M.K., Nguyen K.T., Lee J.E., Maier S.F. Dynamic regulation of the proinflammatory cytokine, interleukin-1beta: molecular biology for non-molecular biologists. Life Sci. 1999, 65:449-481.
46. Yao T., Cohen R.E. A cryptic protease couples deubiquitination and degradation by the proteasome. Nature 2002, 419:403-407.
47. Zheng H., Qian J., Varghese B., Baker D.P., Fuchs S. Ligand-stimulated downregulation of the alpha interferon receptor: role of protein kinase D2. Mol. Cell. Biol. 2011, 31:710-720.